Nu-Med Plus Inc 的盈利质量评分为 B/38.841022。该评分基于盈利能力、增长、现金生成与资本分配以及杠杆四个维度。
Nu-Med Plus Inc 何时发布财报?
Nu-Med Plus Inc 的下一份财报预计在 2026-07-14 发布
Nu-Med Plus Inc 的预期收益是多少?
根据华尔街分析师的预测,Nu-Med Plus Inc 的预期收益为 $
Nu-Med Plus Inc 是否超出收益预期?
Nu-Med Plus Inc 最近的收益为 $, 预期。
关键数据
前收盘价
$0.0152
开盘价
$0.0174
当日区间
$0.0152 - $0.0174
52周范围
$0.0097 - $0.06
交易量
40.0K
平均成交量
22.5K
股息收益率
--
每股收益(TTM)
-0.00
市值
$1.2M
什么是 NUMD?
Nu-Med Plus, Inc. engages in the design, development, and marketing of technologies utilizing nitric oxide in the medical device field. The company is headquartered in Salt Lake City, Utah and currently employs 2 full-time employees. The company went IPO on 2013-08-02. The company focuses on the creation of a nitric oxide (NO) generating formulation, a hospital bedside NO delivery system, a clinical unit for use in medical clinics and rehabilitation centers and a mobile rechargeable device to deliver nitric oxide gas to offer solutions to hospitals, health systems and the medical community throughout the world. Hospital NO Unit delivers a continuous intra-breath concentration of therapeutic NO to patients who are on a ventilator in a hospital setting. The Clinical Delivery System is a simplified version of the hospital unit. Portable Delivery System delivers NO to the patient at prescribed intervals for 24 hours per day at controlled doses by means of a nasal cannula or a face mask. Reagent Delivery offers a range of concentrations and flow rates of NO.